Ischemic Stroke Clinical Trial
— NESAOfficial title:
Neuromuscular Electrical Stimulation in Acute Ischemic Stroke
Verified date | June 2020 |
Source | Zealand University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to examine the added effect of NeuroMuscular Electric Stimulation
(NMES) in addition to exercise therapy in the acute phase of ischemic stroke.
This randomized controlled trial includes 50 patients allocated to either control or
intervention.
The inclusion, test, training and re-test will be provided during the first 14 days after
ictus, starting day 1 or 2 after ictus and a follow-up at day 90.
The exercise training with external NMES is done with the patient every weekday for 12
minutes.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | December 2020 |
Est. primary completion date | June 3, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Acute ischemic apoplexy and paresis in lower extremity, verified with picture diagnosis (CT/MR) or clinically diagnosed. - Leg palsy equalizes 2-4 - Modified Ranking Scale(mRS) =0-1 - Cognitive function adequate to participate Exclusion Criteria: - Patients with dementia and/or malign diseases - Pregnancy - Epilepsy - Total loss of sensation - Pacemaker - Previous or current blood clot in the leg - Untreated depression - Untreated alcohol or drug abuse - Untreated hypertension - Heart disease which limits function |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Neurology | Roskilde |
Lead Sponsor | Collaborator |
---|---|
Zealand University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The six Minute-Walk Test | The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway. | Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks. | |
Secondary | Fugl Meyer Assessment | The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia | Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks. | |
Secondary | Sit to stand | Sit-to-stand is a mechanically demanding task demanding task | Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks. | |
Secondary | Timed Up and Go | The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance. | Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks. | |
Secondary | EuroQOL 5 domain | A self-reported outcome measure of health-related quality of life, covering 5 dimensions (movement, personal care, everyday activities, pain/discomfort and anxiety/depression). Is translated and validated for use in a Danish population. | Change from day 14 post ictus to day 90 post ictus. | |
Secondary | 10 meter walk test | The 10 Metre Walk Test is a performance measure used to assess walking speed in metres per second over a 10 meter distance. | Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks. | |
Secondary | Montreal Cognitive Assessment (MoCA) | The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal. | Change from day 14 post ictus to day 90 post ictus. | |
Secondary | Becks Depression Inventory | Becks Depression Inventory is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression | Change from day 14 post ictus to day 90 post ictus. | |
Secondary | Guralnik | Balance test assessed by the ability to stand for 10 seconds without support in each of the following positions: total feet, semitandem and full tandem | Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A |